Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $3.3 million.

  • Marker Therapeutics' Total Current Liabilities fell 331.82% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 331.82%. This contributed to the annual value of $3.5 million for FY2024, which is 1267.07% up from last year.
  • As of Q3 2025, Marker Therapeutics' Total Current Liabilities stood at $3.3 million, which was down 331.82% from $4.3 million recorded in Q2 2025.
  • Marker Therapeutics' 5-year Total Current Liabilities high stood at $13.5 million for Q2 2022, and its period low was $2.0 million during Q2 2024.
  • Over the past 5 years, Marker Therapeutics' median Total Current Liabilities value was $4.1 million (recorded in 2021), while the average stood at $5.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 13806.7% in 2022, then crashed by 7832.14% in 2023.
  • Over the past 5 years, Marker Therapeutics' Total Current Liabilities (Quarter) stood at $12.9 million in 2021, then tumbled by 39.68% to $7.8 million in 2022, then tumbled by 60.49% to $3.1 million in 2023, then increased by 12.67% to $3.5 million in 2024, then fell by 3.42% to $3.3 million in 2025.
  • Its Total Current Liabilities stands at $3.3 million for Q3 2025, versus $4.3 million for Q2 2025 and $2.5 million for Q1 2025.